Delaney Dennis R Raises Stake in Novo Nordisk A/S $NVO

Key Points

• Delaney Dennis R increased its holdings in Novo Nordisk A/S by 25.0%, owning 26,710 shares valued at approximately $1.84 million after acquiring an additional 5,350 shares during the last quarter.
• Analyst ratings for Novo Nordisk A/S are mixed, with UBS downgrading it to "neutral" while Sanford C. Bernstein upgraded it to "outperform"; the stock has a consensus target price of $77.50.
• Novo Nordisk A/S recently announced a semi-annual dividend of $0.4119 with a dividend yield of 240.0%, despite a low payout ratio of 22.53%.

Delaney Dennis R grew its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 25.0% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 26,710 shares of the company's stock after acquiring an additional 5,350 shares during the quarter. Delaney Dennis R's holdings in Novo Nordisk A/S were worth $1,844,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in NVO. Unified Investment Management purchased a new stake in Novo Nordisk A/S during the second quarter valued at about $692,000. Acadian Asset Management LLC boosted its holdings in Novo Nordisk A/S by 15,919.9% during the 1st quarter. Acadian Asset Management LLC now owns 1,044,658 shares of the company's stock valued at $72,523,000 after acquiring an additional 1,038,137 shares during the period. Guild Investment Management Inc. grew its position in Novo Nordisk A/S by 20.7% during the 2nd quarter. Guild Investment Management Inc. now owns 36,995 shares of the company's stock worth $2,553,000 after acquiring an additional 6,345 shares during the last quarter. Norden Group LLC lifted its position in Novo Nordisk A/S by 216.3% in the second quarter. Norden Group LLC now owns 96,332 shares of the company's stock valued at $6,649,000 after purchasing an additional 65,877 shares during the last quarter. Finally, Farther Finance Advisors LLC boosted its stake in shares of Novo Nordisk A/S by 48.7% during the second quarter. Farther Finance Advisors LLC now owns 103,138 shares of the company's stock valued at $7,119,000 after purchasing an additional 33,794 shares during the period. Institutional investors own 11.54% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. UBS Group downgraded shares of Novo Nordisk A/S from a "buy" rating to a "neutral" rating in a research note on Tuesday, August 5th. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from a "market perform" rating to an "outperform" rating in a research report on Tuesday, September 9th. HSBC set a $70.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, October 1st. Morgan Stanley downgraded Novo Nordisk A/S from an "overweight" rating to an "underweight" rating and reduced their price target for the company from $59.00 to $47.00 in a report on Monday, September 29th. Finally, Dbs Bank raised Novo Nordisk A/S from a "strong sell" rating to a "hold" rating in a research report on Friday, August 22nd. Two analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $77.50.

Novo Nordisk A/S Stock Performance

Shares of NVO opened at $56.95 on Monday. The company has a 50-day simple moving average of $55.44 and a two-hundred day simple moving average of $63.11. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.56. The firm has a market capitalization of $254.27 billion, a PE ratio of 15.64, a price-to-earnings-growth ratio of 2.58 and a beta of 0.68. Novo Nordisk A/S has a one year low of $45.05 and a one year high of $120.56.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share for the quarter, topping analysts' consensus estimates of $0.93 by $0.04. The firm had revenue of $11.69 billion for the quarter, compared to the consensus estimate of $77.51 billion. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%. On average, analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The firm also recently announced a semi-annual dividend, which was paid on Tuesday, August 26th. Stockholders of record on Monday, August 18th were given a $0.4119 dividend. The ex-dividend date of this dividend was Monday, August 18th. This represents a dividend yield of 240.0%. Novo Nordisk A/S's dividend payout ratio is currently 22.53%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.